A safety evaluation of budesonide MMX for the treatment of ulcerative colitis

References

• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.
   PubMed Web of Science ®Google Scholar
• IBSEN Study Group, Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Argollo M, Fiorino G, Hindryckx P, et al. Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017;85:103–116.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology. 2002;123:393–395.
   Google Scholar
• Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory boweldisease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.
   PubMed Web of Science ®Google Scholar
• Saibeni S, Meucci G, Papi C, et al. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol. 2014;8(8):949–962.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosisand medical management. J Crohns Colitis. 2017 Jan;11(1):3–25.
   PubMed Web of Science ®Google Scholar
• Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther. 2000;14(11):1419–1428.
   PubMed Web of Science ®Google Scholar
• Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther. 2002;16(8):1509–1517.
   PubMed Web of Science ®Google Scholar
• Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Sys Rev. 2008; 3.
   Google Scholar
• Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100(8):1780–1787.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;1:CD002913.
   Google Scholar
• Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;10:CD007698.
   Google Scholar
• Peña AS, Kolkman JJ, Greinwald R, et al. Pharmacokinetics after single and multiple oral dosing of budesonide pH-modified-release capsule in patients with distal ulcerative colitis. Proceedings of Falk Workshop on Topical Steroids in Gastroenterology and Hepatology; Berlin, Germany, 2003 Jun 14. Dignass A, Gross V, Buhr HJ, James OFW, editors. Kluwer Academic Publishers, Dordrecht, The Netherlands: p.30–6.
   Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):451–468.
   PubMed Web of Science ®Google Scholar
• Stark JG, Werner S, Homrighausen S, et al. Pharmacokinetic/pharmacodynamics modeling of total lymphocytes and selected subtypes after oral budesonide. Pharmacokinet Pharmacodyn. 2006;33(4):441–459.
   Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57:303–316.
   PubMed Web of Science ®Google Scholar
• Bezzio C, Fascì-Spurio F, Viganò C, et al. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. Expert Rev Gastroenterol Hepatol. 2017;11(1):33–41.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006;24(7):1087–1097.
   PubMed Web of Science ®Google Scholar
• Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61(1):31–38.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Kovács A, Vergauwe P, et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis. 2010;4(2):153–160.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218–1226.
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63:433–441.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Danese S, D’Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41:409–418.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Cohen RD, Sandborn WJ, et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohns Colitis. 2017;11(7):785–791.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Danese S, Ballard DE, et al. Efficacy of Budesonide MMx® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology. 2012;142(5 Suppl 1):S–564.
   Web of Science ®Google Scholar
• Lichtenstein GR, Travis S, Danese S, et al. Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis. J Crohns Colitis. 2015;9:738–746.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Danese S, Ballard ED, et al. Effect of budesonide MMX 6 mg on the hypothalamic–pituitary–adrenal (HPA) axis in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology. 2012;142(Suppl1):S785.
   Google Scholar
• Landi S, Mezzina N, Carmagnola S, et al. Role, efficacy and safety of budesonide-MMX in ulcerative colitis in real life. A study in three Italian third-level centers. Accepted as Poster Presentation at 13th Congress of European Crohn’s and Colitis Organization (Vienna, 14–17 Feb 2018).
   Google Scholar
• Karolewska-Bochenek K, Dziekiewicz M, Banaszkiewicz A. Budesonide MMX in paediatric patients with ulcerative colitis. J Crohns Colitis. 2017;11:1402.
   PubMedGoogle Scholar
• Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis. 2009;15:25–28.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br J Clin Pharmacol. 2017. Epub ahead of print. DOI:10.1111/bcp.13456
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599.
   PubMed Web of Science ®Google Scholar
• Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut. 1996;39:82–86.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363–371.
   PubMed Web of Science ®Google Scholar
• Cino M, Greenberg GR. Bone mineral density in Crohn’s disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002;97:915–921.
   PubMed Web of Science ®Google Scholar
• Schoon EJ, Bollani S, Mills PR, et al. Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–121.
   PubMed Web of Science ®Google Scholar
• Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992;326:226–230.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD002913.
   PubMed Web of Science ®Google Scholar
• Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017;49:338–358.
   PubMedGoogle Scholar